for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Translate Bio Inc

TBIO.O

Latest Trade

14.78USD

Change

0.03(+0.20%)

Volume

6,535,043

Today's Range

14.01

 - 

15.08

52 Week Range

6.80

 - 

28.09

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.75
Open
14.91
Volume
6,535,043
3M AVG Volume
43.71
Today's High
15.08
Today's Low
14.01
52 Week High
28.09
52 Week Low
6.80
Shares Out (MIL)
74.24
Market Cap (MIL)
1,095.10
Forward P/E
-18.67
Dividend (Yield %)
--

Next Event

Translate Bio Inc Annual Shareholders Meeting

Latest Developments

More

Translate Bio Announces Second Quarter 2020 Financial Results And Reviews Recent Progress

Translate Bio Announces Pricing Of Public Offering Of Common Stock

Translate Bio Announces Proposed Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Translate Bio Inc

Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The MRT product candidate for the lung, MRT5005, is designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization.

Industry

Biotechnology & Drugs

Contact Info

29 Hartwell Ave

LEXINGTON, MA

02421-3102

United States

+1.617.9457361

http://translate.bio/

Executive Leadership

Daniel S. Lynch

Independent Chairman of the Board

Ronald C. Renaud

President, Chief Executive Officer, Director

Michael W. Heartlein

Founder, Executive Vice President

John R. Schroer

Chief Financial Officer, Treasurer

Paul Burgess

Chief Operating Officer, Chief Legal Officer

Key Stats

1.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.1K
EPS (USD)

2018

-3.640

2019

-2.200

2020(E)

-0.790
Price To Earnings (TTM)
--
Price To Sales (TTM)
41.91
Price To Book (MRQ)
3.77
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-30.02
Return on Equity (TTM)
-27.17

Latest News

Latest News

EU pays $384 million for Sanofi-GSK COVID vaccine as WHO scheme deadline looms

The European Union has agreed to buy a potential COVID-19 vaccine from Sanofi and GSK in its second such deal to secure supplies, as a deadline for joining the World Health Organization's (WHO) vaccine purchase programme looms.

Sanofi France chief sees coronavirus vaccine priced below 10 euros

A coronavirus vaccine that Sanofi <SASY.PA> is developing with Britain's GlaxoSmithKline <GSK.L> is likely to be priced at less than 10 euros ($11.80) per shot if it is approved for use, Sanofi's chief in France said on Saturday.

Sanofi, GSK launch trial for COVID-19 protein-based vaccine

French drugmaker Sanofi and Britain's GlaxoSmithKline said they had started a clinical trial of their protein-based COVID-19 vaccine candidate, and aimed to reach the final testing stage by December.

Delivering super-cooled COVID-19 vaccine a daunting challenge for some countries

Getting a coronavirus vaccine from manufacturing sites to parts of the developing world supply will be an immense challenge, given the need to store some vials at temperatures as low as minus 80 Celsius (-112 Fahrenheit), Deutsche Post warned on Tuesday.

Delivering super-cooled COVID-19 vaccine a daunting challenge for some countries

Getting a coronavirus vaccine from manufacturing sites to some parts of the world with rural populations and unreliable electricity supply will be an immense challenge, given the need to store some vials at temperatures as low as minus 80 degrees Celsius (-112 Fahrenheit...

RPT-EXCLUSIVE-Sanofi more confident about its coronavirus vaccines

Sanofi's confidence in its coronavirus vaccine candidates has increased this summer as the French drugmaker prepares to start clinical trials, its chief executive told Reuters.

Exclusive: Sanofi more confident about its coronavirus vaccines

Sanofi's confidence in its coronavirus vaccine candidates has increased this summer as the French drugmaker prepares to start clinical trials, its chief executive told Reuters.

Translate Bio, Sanofi COVID-19 vaccine candidate produces immune response in animal studies

Translate Bio Inc <TBIO.O> said on Tuesday that an experimental coronavirus vaccine it developed with French drugmaker Sanofi SA <SASY.PA> induced immune response in non-human studies, with trials in humans expected to start in November.

Translate Bio, Sanofi COVID-19 vaccine candidate produces immune response in animal studies

Translate Bio Inc said on Tuesday that an experimental coronavirus vaccine it developed with French drugmaker Sanofi SA induced immune response in early-stage non-human primate studies.

FACTBOX-U.S. pours billions into securing access to coronavirus vaccine candidates

As drugmakers race to develop vaccines and therapies for the novel coronavirus, the United States is rushing to secure access to them. The U.S. government has agreed to invest more than $7 billion in vaccines and has funded more than 30 projects, including for diagnostics...

Sanofi lifts earnings view as Regeneron stake sale boosts second quarter

Sanofi <SASY.PA> raised its 2020 earnings forecast on Wednesday after its second-quarter results were boosted by cost cuts and the sale of most of its 20.6% stake in U.S. company Regeneron <REGN.O>, although revenue was hit by the coronavirus crisis.

FACTBOX-U.S. pours billions into development of coronavirus vaccines, tests

(Updates with BARDA investment in Novavax vaccine, new grants to Regeneron's and AstraZeneca's therapies, updates development stage for AstraZeneca vaccine and diagnostics table) July 7 (Reuters) - As drugmakers race to develop vaccines, tests and therapies for the novel...

UPDATE 2-Tesla to make molecule printers for COVID-19 vaccine developer CureVac

Tesla Inc is building mobile molecule printers to help make the potential COVID-19 vaccine being developed by CureVac in Germany, the electric-car maker's CEO Elon Musk tweeted on Wednesday.

Musk says Tesla is building 'RNA microfactories' for CureVac

Tesla Inc is building "RNA microfactories" for coronavirus vaccine developer CureVac in Germany, the electric carmaker's chief executive officer, Elon Musk, tweeted on Wednesday.

BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial

A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.

Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech

Singapore's state investor Temasek and other investors are injecting $250 million into German biotech company BioNTech <BNTX.O>, which is developing an experimental vaccine against the coronavirus with pharmaceutical giant Pfizer <PFE.N>.

French drugmaker Sanofi to cut up to 1,680 jobs in Europe

French drugmaker Sanofi <SASY.PA>, which employs more than 100,000 people worldwide, confirmed on Friday it will axe up to 1,680 jobs in Europe to cut costs and lift profits.

BRIEF-Translate Bio Announces Pricing Of Public Offering Of Common Stock

* TRANSLATE BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Exclusive: Sanofi considers job cuts as CEO seeks to reduce costs - sources

Sanofi <SASY.PA> is considering cutting hundreds of jobs and will discuss potential steps with staff representatives over the coming days, five sources said on Thursday, the latest move by the French drugmaker's chief executive Paul Hudson to cut costs.

BRIEF-Translate Bio Announces Proposed Public Offering Of Common Stock

* TRANSLATE BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up